16th Annual Wells Fargo Industrials & Materials Conference
Logotype for Ingersoll Rand Inc

Ingersoll Rand (IR) 16th Annual Wells Fargo Industrials & Materials Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Ingersoll Rand Inc

16th Annual Wells Fargo Industrials & Materials Conference summary

10 Jun, 2026

Demand and growth trends

  • Short cycle demand is improving, with normalization of trends and prior headwinds from tariffs and China largely behind.

  • About 20%-25% of original equipment business is long cycle, with healthy order funnels and timing-driven revenue recognition.

  • Aftermarket represents roughly 40% of ITS, showing steady growth and recurring revenue as a key initiative.

  • Americas account for about half of revenue, Europe a third, and Asia Pacific 15%, with China now stabilized at 11%.

  • India is the fastest-growing region, while Europe remains stable and China is showing organic order momentum.

Pricing, costs, and margin dynamics

  • Pricing has normalized to 1%-2% annual increases after elevated levels due to tariffs; China remains a tougher pricing environment.

  • Tariff-related cost headwinds have been offset by pricing, resulting in margin dilution but dollar neutrality; normalization expected in the back half of the year.

  • Raw material inflation and Middle East tensions are being managed through staggered, business-specific pricing actions.

  • In-region-for-region manufacturing model helps manage supply chain and lead times, with limited intercompany exposure.

  • Seasonal volume increases and productivity improvements, along with restructuring, are expected to drive margin expansion in the second half.

Segment and regional performance

  • ITS sees 75% of original equipment as short to medium cycle, with order-to-shipment cycles of 30-90 days; long cycle projects take 6-18 months.

  • PST has achieved three consecutive quarters of 30%+ EBITDA margins, driven by life sciences and biopharma growth.

  • Life sciences business is $600M-$700M, with medical, biopharma, and device components as key drivers; recent bolt-ons enhance capabilities.

  • M&A activity remains robust, with a focus on bolt-ons across both segments and a healthy pipeline of deals under LOI.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more